NewGen Prices $1.25 Million Public Offering of 17.9 Million Shares

GlobeNewswire··US·Read original
2▲0 ▼1Impact / 5
Summary · why it matters

NewGenIvf Group Limited announced the pricing of a reasonable best efforts public offering expected to raise gross proceeds of approximately $1.25 million before deducting placement agent fees and other offering expenses. The offering consists of 17,857,143 Ordinary Shares or Pre-Funded Warrants in lieu thereof, priced at $0.07 per Common Share, or $0.06999 for each Pre-Funded Warrant, which equals the public offering price per Ordinary Share minus an exercise price of $0.00001 per Pre-Funded Warrant. The Pre-Funded Warrants will be immediately exercisable and may be exercised at any time until exercised in full, with the number of Ordinary Shares in the offering decreased on a one-for-one basis for each Pre-Funded Warrant sold. The transaction is expected to close on or about September 30, 2026, subject to customary closing conditions, and the Company expects to use the net proceeds together with existing cash for investment in K25.ai, restructuring of debt securities, working capital including manufacturing and deployment of Nodexus machines in the cell-sorting business, and general corporate purposes. Aegis Capital Corp. is acting as exclusive placement agent, Han Kun Law Offices LLP is acting as U.S. counsel to the Company, and Kaufman & Canoles, P.C. is acting as U.S. counsel to Aegis Capital Corp. A registration statement on Form F-1 previously filed with the SEC on August 20, 2026 was declared effective on September 28, 2026.

Impact on assets 2

Health Care▼
Aging Population▲

Off-coverage companies 2

K25.aii
Private▲ PositiveCapitalrelevance

NewGen stated it will use offering proceeds to invest in K25.ai.

Nodexus Inc.i
Private▲ PositiveCapitalrelevance

Offering proceeds will fund manufacturing and deployment of Nodexus cell-sorting machines.